explore -WSS

explore

author：fashion 2025-09-27 12:56:14 - browse：68

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Key Senate panel to consider PBM, drug pricing reform package

entertainment

WSS

Brain injuries and the importance of a second opinion

ASCO Daily Recap: CAR

Elevance PBM president out as customers face prescription chaos

What is microchimerism and how does it affect maternal health?

Medicare proceeds with plan to claw back hospital funds

An outdated Medicare rule harms dementia patients with anxiety

focus

explore

Wikipedia

Peter Hotez and the public health issue of online harassment

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Sports medicine is finally prioritizing gender equality

For pregnant people, addiction treatment shouldn't mean a call to child protective services

After affirmative action ruling, medical educators look to 'holistic review'

Elevance PBM president out as customers face prescription chaos

New air purifier tech could be key to improving indoor air quality

Infant mortality in U.S. rose last year for first time in decades: CDC

New air purifier tech could be key to improving indoor air quality

Humans aren't the only ones with an imagination. Rats have it too

focus

FTC loses bid to block Novant's North Carolina hospital merger

Illumina board agrees to spin off Grail, as divestment plans proceed

Finland to offer bird flu vaccine to select groups of people, a possible global first

ASCO Takeaways: Winners, snoozers, and the art of cancer care

All of Us, NIH's precision medicine initiative, gets a big boost

How neuroscience research could help beat back brain cancer

hotspot

leisure time

entertainment

knowledge